Welcome to our dedicated page for Atlas Energy news (Ticker: CANSF), a resource for investors and traders seeking the latest updates and insights on Atlas Energy stock.
Atlas Energy Corp. (CANSF) generates news that reflects its role as an international upstream oil and gas royalty and streaming company and its evolution from Willow Biosciences Inc. Company announcements have described a significant recapitalisation, the completion of a TSX Venture Exchange listing under the symbol ATLE, and changes to its trading status on U.S. over-the-counter markets.
Earlier news releases issued under Willow Biosciences Inc. provide important background for investors tracking this symbol. Those disclosures cover the sale of Willow’s wholly owned operating subsidiary, the resulting status of Willow as having no active business, and the subsequent reorganization and investment agreement that provided for a private placement, new executive leadership, a reconstituted board of directors, and a name change to Atlas Energy Corp. They also outline the expected transition of the listing from the Toronto Stock Exchange to the TSX Venture Exchange and the use of the TSXV Sandbox program.
More recent communications under the Atlas Energy name highlight the company’s upstream royalty and streaming focus, the initial recapitalisation, and its status as a TSXV Sandbox issuer. News items also describe the voluntary delisting of the company’s common shares from the OTCQB and continued trading on the TSX Venture Exchange and OTC Pink market.
Investors following CANSF-related news can review this history to understand how the business focus shifted from precision fermented ingredients and biomanufacturing under Willow Biosciences to oil and gas royalty and streaming interests under Atlas Energy Corp., as well as how the company’s capital structure and listing venues have changed over time.
Willow Biosciences has entered a multi-year supply agreement with Cellular Goods to provide ultra-pure, biosynthetically produced cannabigerol (CBG) for use in skincare products set to launch in autumn 2021. The first shipment is scheduled for July 2021. Willow's CBG has demonstrated safety and beneficial properties on human skin, making it a suitable ingredient for cosmetics in the evolving UK market, where CBG is now approved for use. This agreement marks Willow's first commercial supply of CBG, enhancing its position in the growing cannabinoid sector.
Willow Biosciences Inc. (CANSF) announced participation in a panel at SynBioBeta's conference on May 26, 2021, focusing on synthetic biology in biopharma. The event features industry leaders discussing advancements in bioproduction. Willow, specializing in sustainable cannabinoid production through yeast-based biosynthesis, aims to showcase its innovative approaches. This participation supports Willow's ongoing efforts in the biotech sector, particularly in creating high-purity, plant-derived ingredients.
Willow Biosciences, a Canadian biotechnology firm, has been added to the Cannabis ETF (THCX) on NYSE Arca as of May 18, 2021. This milestone, timed with the company's shift to commercialization of cannabigerol (CBG), aims to attract a broader investor base interested in the rapidly growing cannabinoid market. As the only public entity focused on biosynthetically producing cannabinoids, Willow's innovative manufacturing process promises ultra-pure products with a low environmental impact. The inclusion in THCX aligns with its targeted approach in the expanding cannabis sector.
Willow Biosciences Inc. (OTCQX: CANSF) announced positive results from a series of studies with Signum Biosciences, showing the safety and anti-inflammatory benefits of their cannabigerol (CBG). Willow CBG demonstrated no irritation on skin and eyes, and displays potent antioxidant and anti-inflammatory properties, surpassing that of CBD in certain tests. These findings pave the way for commercialization in skincare, with the full data set to be shared at the Society for Investigative Dermatology meeting on May 3, 2021. Willow's CBG could become a key player in the cannabinoid market.
Willow Biosciences Inc. (OTCQX: CANSF) has successfully completed its first commercial scale fermentation run of cannabigerol (CBG). The company is pleased with the yield and quality achieved. With over two years as a public entity, Willow has built a strong R&D team and partnered with Albany Molecular Research for development. Production is set to meet growing demand for ultra-pure CBG, with agreements being finalized with multiple clients. Additionally, preliminary safety data from Signum Biosciences indicates CBG's potential as a cosmetic ingredient, showcasing its antioxidant and anti-inflammatory properties.
Willow Biosciences Inc. has successfully closed an upsized bought deal offering, raising approximately $28.75 million through the sale of 17,424,800 common shares at $1.65 each. The offering attracted significant participation from cornerstone and institutional investors. Proceeds will be used to expand market access for Willow's cannabinoid portfolio, expedite commercialization, and enhance manufacturing capacity. With the first cannabinoid commercialization expected in Q1 2021, Willow aims to leverage its strong financial position to pursue growth opportunities.
Willow Biosciences Inc. (OTCQX: CANSF) is collaborating with the University of Lethbridge and the University of Calgary to investigate the therapeutic effects of non-psychoactive cannabinoids on intestinal inflammation, abdominal pain, and depression. Funded by Alberta Innovates, the study will utilize four non-plant-derived cannabinoids in preclinical models. The project, led by Dr. Aaron Gruber, aims to explore new treatment options for inflammatory conditions. This partnership allows Willow to leverage its manufacturing technologies with minimal investment while positioning itself as a leader in the emerging cannabinoid market.
Willow Biosciences Inc. (CANSF) has successfully developed a scalable process for producing cannabigerol (CBG) with over 99% purity and no detectable THC at a 500-litre scale. Collaborating with Albany Molecular Research, the company optimized its proprietary yeast strain and downstream purification methods, enabling cost-effective and environmentally sustainable production. CEO Trevor Peters highlighted a significant market opportunity in high-purity cannabinoids, anticipating commercialization in early 2021. Initial demand for CBG samples has emerged from global markets including Canada and the U.S.